Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Indication and clinical use:
AREXVY is a vaccine indicated for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.
Pediatrics: Safety and efficacy not assessed.
Geriatrics: Clinical studies include participants ≥65 years of age, and their data contributes to the overall assessment of safety and efficacy of AREXVY.
Relevant warnings and precautions:
- There is no data for the use of AREXVY in pregnant individuals. Not recommended during pregnancy or in breast-feeding/lactating individuals
- Postpone vaccination in individuals suffering from an acute severe febrile illness
- Syncope
- Caution driving and operating machinery
- Caution in individuals with thrombocytopenia or any coagulation disorder
- Protective immune response may not be elicited in all vaccinees
- Systemic immunosuppressive medications and immunodeficiency
For more information:
Please consult the Product Monograph at gsk.ca/AREXVY/PM for important information relating to warnings, precautions, adverse reactions, drug interactions, and dosing. To request a Product Monograph or to report an adverse event, please call 1-800-387-7374.
